Search

Artificial intelligence (AI) is becoming increasingly important, especially in the medical field. While AI has been used in medicine for some time, its growth in the last decade is remarkable. Specifically, machine learning (ML) and deep learning (DL) techniques in medicine have been increasingly adopted due to the growing abundance of health-related data, the improved suitability of such techniques for managing large datasets, and more computational power. ML and DL methodologies are fostering the development of new "intelligent" tools and expert systems to process data, to automatize human–machine interactions, and to deliver advanced predictive systems that are changing every aspect of the scientific research, industry, and society. The Italian scientific community was instrumental in advancing this research area. This article aims to conduct a comprehensive investigation of the ML and DL methodologies and applications used in medicine by the Italian research community in the last five years. To this end, we selected all the papers published in the last five years with at least one of the authors affiliated to an Italian institution that in the title, in the abstract, or in the keywords present the terms "machine learning" or "deep learning" and reference a medical area. We focused our research on journal papers under the hypothesis that Italian researchers prefer to present novel but well-established research in scientific journals. We then analyzed the selected papers considering different dimensions, including the medical topic, the type of data, the pre-processing methods, the learning methods, and the evaluation methods. As a final outcome, a comprehensive overview of the Italian research landscape is given, highlighting how the community has increasingly worked on a very heterogeneous range of medical problems. [ABSTRACT FROM AUTHOR]

Drug side effects (DSEs) or adverse drug reactions (ADRs) are a major concern in the healthcare industry, accounting for a significant number of annual deaths in Europe alone. Identifying and predicting DSEs early in the drug development process is crucial to mitigate their impact on public health and reduce the time and costs associated with drug development. Objective: In this study, our primary objective is to predict multiple drug side effects using 2D chemical structures, especially for COVID-19, departing from the conventional approach of relying on 1D chemical structures. We aim to develop a novel model for DSE prediction that leverages the CNN-based transfer learning architecture of ResNet152V2. Motivation: The motivation behind this research stems from the need to enhance the efficiency and accuracy of DSE prediction, enabling the pharmaceutical industry to identify potential drug candidates with fewer adverse effects. By utilizing 2D chemical structures and employing data augmentation techniques, we seek to revolutionize the field of drug side-effect prediction. Novelty: This study introduces several novel aspects. The proposed study is the first of its kind to use 2D chemical structures for predicting drug side effects, departing from the conventional 1D approaches. Secondly, we employ data augmentation with both conventional and diffusion-based models (Pix2Pix), a unique strategy in the field. These innovations set the stage for a more advanced and accurate approach to DSE prediction. Results: Our proposed model, named CHEM2SIDE, achieved an impressive average training accuracy of 0.78. Moreover, the average validation and test accuracy, precision, and recall were all at 0.73. When evaluated for COVID-19 drugs, our model exhibited an accuracy of 0.72, a precision of 0.79, a recall of 0.72, and an F1 score of 0.73. Comparative assessments against established transfer learning and machine learning models (VGG16, MobileNetV2, DenseNet121, and KNN) showcased the exceptional performance of CHEM2SIDE, marking a significant advancement in drug side-effect prediction. Conclusions: Our study introduces a groundbreaking approach to predicting drug side effects by using 2D chemical structures and incorporating data augmentation. The CHEM2SIDE model demonstrates remarkable accuracy and outperforms existing models, offering a promising solution to the challenges posed by DSEs in drug development. This research holds great potential for improving drug safety and reducing the associated time and costs. [ABSTRACT FROM AUTHOR]